WO2017123610A3 - Bactéries modifiées pour détoxifier les molécules délétères - Google Patents

Bactéries modifiées pour détoxifier les molécules délétères Download PDF

Info

Publication number
WO2017123610A3
WO2017123610A3 PCT/US2017/012982 US2017012982W WO2017123610A3 WO 2017123610 A3 WO2017123610 A3 WO 2017123610A3 US 2017012982 W US2017012982 W US 2017012982W WO 2017123610 A3 WO2017123610 A3 WO 2017123610A3
Authority
WO
WIPO (PCT)
Prior art keywords
detoxify
bacteria engineered
deleterious molecules
deleterious
molecules
Prior art date
Application number
PCT/US2017/012982
Other languages
English (en)
Other versions
WO2017123610A2 (fr
Inventor
Dean Falb
Jonathan W. Kotula
Vincent M. Isabella
Paul F. Miller
Adam B. FISHER
Yves Millet
Suman MACHINANI
Original Assignee
Synlogic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/020530 external-priority patent/WO2016141108A1/fr
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/fr
Priority claimed from PCT/US2016/039444 external-priority patent/WO2016210384A2/fr
Priority claimed from PCT/US2016/050836 external-priority patent/WO2017074566A1/fr
Priority claimed from PCT/US2016/069052 external-priority patent/WO2017123418A1/fr
Application filed by Synlogic, Inc. filed Critical Synlogic, Inc.
Publication of WO2017123610A2 publication Critical patent/WO2017123610A2/fr
Publication of WO2017123610A3 publication Critical patent/WO2017123610A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des bactéries obtenues par génie génétique, des compositions pharmaceutiques les comprenant, et des procédés de détoxification de molécules délétères.
PCT/US2017/012982 2016-01-11 2017-01-11 Bactéries modifiées pour détoxifier les molécules délétères WO2017123610A2 (fr)

Applications Claiming Priority (34)

Application Number Priority Date Filing Date Title
US201662277438P 2016-01-11 2016-01-11
US62/277,438 2016-01-11
US201662291468P 2016-02-04 2016-02-04
US201662291461P 2016-02-04 2016-02-04
US201662291470P 2016-02-04 2016-02-04
US62/291,461 2016-02-04
US62/291,468 2016-02-04
US62/291,470 2016-02-04
PCT/US2016/020530 WO2016141108A1 (fr) 2015-03-02 2016-03-02 Bactéries modifiées pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande imperméabilité de la muqueuse intestinale s'avèrent bénéfiques
USPCT/US2016/020530 2016-03-02
USPCT/US2016/032565 2016-05-13
PCT/US2016/032565 WO2016183532A1 (fr) 2015-05-13 2016-05-13 Bactéries modifiées pour traiter une maladie ou un trouble
US201662347576P 2016-06-08 2016-06-08
US201662347508P 2016-06-08 2016-06-08
US62/347,576 2016-06-08
US62/347,508 2016-06-08
US201662348620P 2016-06-10 2016-06-10
US62/348,620 2016-06-10
US201662354682P 2016-06-24 2016-06-24
US62/354,682 2016-06-24
USPCT/US2016/039444 2016-06-24
PCT/US2016/039444 WO2016210384A2 (fr) 2015-06-25 2016-06-24 Bactéries manipulées pour traiter des maladies métaboliques
US201662362954P 2016-07-15 2016-07-15
US62/362,954 2016-07-15
US201662385235P 2016-09-08 2016-09-08
US62/385,235 2016-09-08
PCT/US2016/050836 WO2017074566A1 (fr) 2015-10-30 2016-09-08 Bactéries modifiées pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande imperméabilité de la muqueuse intestinale s'avèrent bénéfiques
USPCT/US2016/050836 2016-09-08
US201662423170P 2016-11-16 2016-11-16
US62/423,170 2016-11-16
US201662439871P 2016-12-28 2016-12-28
USPCT/US2016/069052 2016-12-28
PCT/US2016/069052 WO2017123418A1 (fr) 2016-01-11 2016-12-28 Bactéries modifiées pour traiter des maladies métaboliques
US62/439,871 2016-12-28

Publications (2)

Publication Number Publication Date
WO2017123610A2 WO2017123610A2 (fr) 2017-07-20
WO2017123610A3 true WO2017123610A3 (fr) 2017-09-28

Family

ID=59312123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/012982 WO2017123610A2 (fr) 2016-01-11 2017-01-11 Bactéries modifiées pour détoxifier les molécules délétères

Country Status (1)

Country Link
WO (1) WO2017123610A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016889B2 (en) 2018-02-23 2024-06-25 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing intestinal paracellular permeability
US20220184147A1 (en) * 2019-03-04 2022-06-16 Northwestem University Bacterial enzymatic conversion of anthracycline chemotherapeutics to reduce toxicity and promote diversity among the intestinal microbiota
CA3142608A1 (fr) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Produits a base de soie, formulations et procedes d'utilisation
CN116585360B (zh) * 2023-05-24 2023-11-14 微康益生菌(苏州)股份有限公司 一种改善慢性肾病的益生菌剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (fr) 1998-12-02 2003-03-26 Univ Boston Reseaux de genes destines a controler l'expression genetique
EP1034787A1 (fr) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Souches de lactobacillus capables de prévenir la diarrhée causée des bactéries pathogènes
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
EP2655624B1 (fr) 2010-12-23 2017-11-29 Biogen MA Inc. Peptides coupleurs et polypeptides les comportant
US9951340B2 (en) 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
C. KING ET AL: "Characterization of Rat and Human UDP-Glucuronosyltransferases Responsible for the in Vitro Glucuronidation of Diclofenac", TOXICOLOGICAL SCIENCES, vol. 61, no. 1, 1 May 2001 (2001-05-01), pages 49 - 53, XP055381612, DOI: 10.1093/toxsci/61.1.49 *
CASTAGIUOLO I ET AL: "Engineered E. coli delivers therapeutic genes to the colonic mucosa", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 12, 1 January 2005 (2005-01-01), pages 1070 - 1078, XP003009139, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3302493 *
KEN-ICHI FUJITA ET AL: "ESTABLISHMENT OF SALMONELLA STRAIN EXPRESSING CATALYTICALLY ACTIVE HUMAN UDP-GLUCURONOSYLTRANSFERASE 1Al (UGTlAl)", LIFE FICICTTCES, 7 April 2000 (2000-04-07), XP055380853, Retrieved from the Internet <URL:http://ac.els-cdn.com/S002432050000521X/1-s2.0-S002432050000521X-main.pdf?_tid=b98c9a7e-5012-11e7-b804-00000aacb361&acdnat=1497342881_e7df786dd1775cc2e9314e5cc1175b62> [retrieved on 20170613] *
M. N. TALLMAN ET AL: "The Contribution of Intestinal UDP-Glucuronosyltransferases in Modulating 7-Ethyl-10-hydroxy-camptothecin (SN-38)-Induced Gastrointestinal Toxicity in Rats", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 320, no. 1, 1 January 2007 (2007-01-01), US, pages 29 - 37, XP055382911, ISSN: 0022-3565, DOI: 10.1124/jpet.106.110924 *
MEGO MICHAL ET AL: "Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study", COMPLEMENTARY THERAPIES IN MEDICINE, vol. 23, no. 3, 4 April 2015 (2015-04-04), pages 356 - 362, XP029170661, ISSN: 0965-2299, DOI: 10.1016/J.CTIM.2015.03.008 *
MOHAMMAD A RATTU ET AL: "Glucarpidase (Voraxaze), a Carboxypeptidase Enzyme for Methotrexate Toxicity", P & T PHARMACY AND THERAPEUTICS JOURNAL, vol. 38, no. 12, 1 December 2013 (2013-12-01), US, pages 732 - 744, XP055381306, ISSN: 1052-1372 *
OUZZINE M ET AL: "Expression of the human UDP-glucuronosyltransferase UGT16 in Escherichia coli", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 339, no. 1-2, 14 February 1994 (1994-02-14), pages 195 - 199, XP025652126, ISSN: 0014-5793, [retrieved on 19940214], DOI: 10.1016/0014-5793(94)80414-1 *
S. CHEN ET AL: "Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 110, no. 47, 4 November 2013 (2013-11-04), US, pages 19143 - 19148, XP055381310, ISSN: 0027-8424, DOI: 10.1073/pnas.1319123110 *
SABINE BECKER ET AL: "O2 as the Regulatory Signal for FNR-Dependent Gene Regulation in Escherichia coli", JOURNAL OF BACTERIOLOGY, 1 August 1996 (1996-08-01), pages 4515 - 4521, XP055363883, Retrieved from the Internet <URL:http://jb.asm.org/content/178/15/4515.full.pdf> [retrieved on 20170411] *
SAUGE-MERLE SANDRINE ET AL: "Enhanced toxic metal accumulation in engineered bacterial cells expressing Arabidopsis thaliana phytochelatin synthase", APPLIED AND ENVIRONMENTAL MICROBIOLOGY,, vol. 69, no. 1, 1 January 2003 (2003-01-01), pages 490 - 494, XP002597461, ISSN: 0099-2240, DOI: 10.1128/AEM.69.1.490-494.2003 *
SAYED K GODA ET AL: "Functional Overexpression and Purification of a Codon Optimized Synthetic Glucarpidase (Carboxypeptidase G2) in Escherichia coli", JOURNAL OF PROTEIN CHEMISTRY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 28, no. 9-10, 13 November 2009 (2009-11-13), pages 435 - 442, XP019771582, ISSN: 1573-4943, DOI: 10.1007/S10930-009-9211-2 *
STEIDLER L ED - CHAN FRANCIS K L ET AL: "GENETICALLY ENGINEERED PROBIOTICS", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL GASTROENTEROLOGY, BAILLIERE TINDALL, LONDON, US, vol. 17, no. 5, 1 January 2003 (2003-01-01), pages 861 - 876, XP009028993, ISSN: 1521-6918, DOI: 10.1016/S1521-6918(03)00072-6 *
XIN LI ET AL: "Cloning of UGT1A9 cDNA from liver tissues and its expression in CHL cells INTRODUCTION", CHINA WORLD J GASTROENTEROL, 1 January 2001 (2001-01-01), XP055383180, Retrieved from the Internet <URL:https://www.wjgnet.com/1007-9327/full/v7/i6/841.htm> DOI: http://dx.doi.org/10.3748/wjg.v7.i6.841 *

Also Published As

Publication number Publication date
WO2017123610A2 (fr) 2017-07-20

Similar Documents

Publication Publication Date Title
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
WO2017095944A8 (fr) Procédés et compositions se rapportant à des chondrisomes provenant de produits sanguins
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
WO2016210384A3 (fr) Bactéries manipulées pour traiter des maladies métaboliques
WO2018229236A3 (fr) Compositions comprenant des souches bactériennes
EP3722412A4 (fr) Nouvelle bactérie bifidobacterium, et composition contenant cette bactérie
CA2956871C (fr) Composes actifs envers des bromodomaines
MY191581A (en) Anti-pd-1 antibodies
WO2016183532A8 (fr) Bactéries modifiées pour traiter une maladie ou un trouble
WO2016149401A3 (fr) Carbamates de pipérazine et procédés de préparation et d&#39;utilisation de ceux-ci
EP4310500A3 (fr) Procédés et compositions pour l&#39;activation de lymphocytes t gamma delta
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
WO2017136795A8 (fr) Bactéries modifiées pour traiter des maladies associées au metabolisme du tryptophane
WO2016060996A3 (fr) Compositions d&#39;interleukine-15 et leurs utilisations
EP3474861A4 (fr) Composés comprenant des hmos pour la prévention et/ou le traitement d&#39;infections virales et/ou bactériennes.
WO2017139697A8 (fr) Bactéries modifiées en vue du traitement de maladies associées à l&#39;hyperammoniémie
WO2016200614A3 (fr) Bactéries modifiées en vue du traitement de maladies associées à l&#39;hyperammoniémie
WO2017083431A3 (fr) Composés à base d&#39;hydroxypyridinone et d&#39;hydroxypyrimidinone pour le traitement d&#39;infections bactériennes
EP4218736A3 (fr) Compositions à base de 15-hepe
MX367669B (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos.
EP3518955A4 (fr) Compositions immunogènes tert et méthodes de traitement les utilisant
WO2017123610A3 (fr) Bactéries modifiées pour détoxifier les molécules délétères
WO2016007540A3 (fr) Compositions et méthodes pour le traitement d&#39;une infection par le virus de la dengue
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EP3722413A4 (fr) Nouvelle bactérie bifidobacterium, et composition contenant cette bactérie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17700590

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17700590

Country of ref document: EP

Kind code of ref document: A2